KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Operating Expenses (2016 - 2025)

Regeneron Pharmaceuticals has reported Operating Expenses over the past 17 years, most recently at $3.0 billion for Q4 2025.

  • Quarterly results put Operating Expenses at $3.0 billion for Q4 2025, up 7.34% from a year ago — trailing twelve months through Dec 2025 was $10.8 billion (up 5.42% YoY), and the annual figure for FY2025 was $10.8 billion, up 5.42%.
  • Operating Expenses for Q4 2025 was $3.0 billion at Regeneron Pharmaceuticals, up from $2.7 billion in the prior quarter.
  • Over the last five years, Operating Expenses for REGN hit a ceiling of $3.0 billion in Q4 2025 and a floor of $1.4 billion in Q1 2021.
  • Median Operating Expenses over the past 5 years was $2.3 billion (2021), compared with a mean of $2.2 billion.
  • Biggest five-year swings in Operating Expenses: skyrocketed 84.09% in 2021 and later dropped 2.46% in 2022.
  • Regeneron Pharmaceuticals' Operating Expenses stood at $2.3 billion in 2021, then fell by 1.92% to $2.3 billion in 2022, then rose by 8.55% to $2.5 billion in 2023, then rose by 13.72% to $2.8 billion in 2024, then grew by 7.34% to $3.0 billion in 2025.
  • The last three reported values for Operating Expenses were $3.0 billion (Q4 2025), $2.7 billion (Q3 2025), and $2.6 billion (Q2 2025) per Business Quant data.